Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Not applicable Interventional

Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

NCT07594483
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Motif XCS System
Device
Lead sponsor
Motif Neurotech, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Not yet recruiting Not applicable Interventional

Augmented Depression Therapy (ADepT) Case Series

NCT07733310
View directory record Official record
Conditions
Depression / Major Depressive Disorder
Interventions
Augmented Depression Therapy (ADepT)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 3 Interventional

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS-SR 50 mg, DVS-SR 100 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Beverly Hills, California • Northridge, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

NCT00105989
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Newport Beach, California • Sherman Oaks, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 28, 2026, 9:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome of Depression & Treatment Response to Citalopram

NCT02330068
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
citalopram
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home

NCT00505518
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Results available

Connectivity Affecting the Antidepressant REsponse Study

NCT02332291
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Assessing Symptomatic Clinical Episodes in Depression

NCT03595579
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

NCT00073203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
R228060, Placebo and Paroxetine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2009 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents

NCT02586688
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active NeuroStar® Transcranial Magnetic Stimulation (TMS), Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Neuronetics
Other
Eligibility
12 Years to 21 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Dothan, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

NCT07592689
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Terminated Phase 3 Interventional

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

NCT01156415
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AGO178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 71 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
95
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 28, 2026, 9:39 AM EDT
Completed No phase listed Observational

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

NCT01385709
View directory record Official record
Conditions
Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, Social Anxiety Disorder
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 28, 2026, 9:39 AM EDT
Not yet recruiting Phase 4 Interventional

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

NCT07369115
View directory record Official record
Conditions
Major Depressive Diorder, Early Life Trauma
Interventions
Lumateperone 42 mg, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 3 Interventional

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

NCT00610506
View directory record Official record
Conditions
Atypical Depression
Interventions
Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional

Study for Evaluating Different Methods of Measuring Depression Treatment Response

NCT00406952
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
electronic diary, Sertraline, Placebo, voice acoustics
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Norwich, Connecticut • Aventura, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00296725
View directory record Official record
Conditions
Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
Interventions
Fluoxetine, Imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional

Early Intervention for Youth at Risk for Bipolar Disorder

NCT01483391
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Enhanced Care, Family-Focused Treatment
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT

NCT00285818
View directory record Official record
Conditions
Depression
Interventions
Mifepristone, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

NCT04969510
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Lafayette, California • Lemon Grove, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

ALTO-300 in Depression

NCT05118750
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-300 oral (PO) tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Culver City, California • Sacramento, California • Santee, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 28, 2026, 9:39 AM EDT
Suspended Phase 2 Interventional

Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder

NCT03787290
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab, Placebo, Whole-Body Hyperthermia
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

NCT05686408
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
Interventions
TNX-601 ER, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 28, 2026, 9:39 AM EDT